Densitas
Densitas is a Halifax-based healthcare AI company providing the intelliMammo platform, which delivers automated mammography image quality, breast density, positioning quality, and breast cancer risk assessments deployed at mammography facilities, health systems, provincial screening programs, and academic centers across North America, the UK, and Germany.
- Company typePrivate
- Founded2015
- HeadquartersHalifax, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Densitas does
Densitas is a Canadian-based, private healthcare AI company that builds and markets a mammography AI suite under the intelliMammo platform. The suite delivers automated breast density assessment (densityAI), image quality and positioning quality evaluation (qualityAI/intelliPGMI), breast cancer risk management (intelliRisk), and an AI assistant for technologist coaching (intelliMaven, a GPT-powered add-on). The technology processes standard DICOM 'for presentation' mammograms, integrates with PACS, RIS, and reporting platforms, and is positioned for compliance with FDA MQSA/EQUIP, CAR MAP, and NAPBC accreditation frameworks. The platform is deployed at health systems, provincial screening programs (notably Atlantic Canada), NHS trusts in the UK, and within research trials in Germany, and is distributed both via direct enterprise sales and through AI marketplaces (Nuance, Blackford) and integration partners (Intelerad, iCAD, ScreenPoint Medical, Ikonopedia, Three Palm Software, TeraRecon).
The company monetizes through enterprise SaaS subscriptions sold to mammography facilities and health systems via demo-led, direct field sales and channel partners; specific pricing is not publicly disclosed. Customer segments span hospital and independent mammography facilities, multi-facility health systems, provincial/national screening programs, breast cancer screening research programs, and high-risk breast clinics. Selected named customers and case studies include Nova Scotia Health, NorthShore University HealthSystem, Leeds Teaching Hospitals NHS Trust, TeleMammography Specialists, and RAD-AID International. The company has stated clinical outcomes such as mammograms meeting positioning criteria improving from approximately 51% to 86% under structured QI programs, and its algorithms have analyzed over 2 million mammograms cumulatively.
Densitas is led by founder and CEO Mo Abdolell and operates from Halifax, Nova Scotia, with regional sites for the U.S. and UK. Strategic direction since 2024 has emphasized product expansion (intelliMaven in April 2024, intelliRisk in November 2024), clinical evidence publication (MAMMO.IQ study in July 2025), and geographic expansion into continental Europe via the DIMASOS 2 procurement. Strategic and distribution partnerships with MTMI, ACR Learning Network, TungstenQI Partners, Mammography Educators, and Intelerad extend its reach and embed the platform into clinical QI workflows. Known outside investors include Innovacorp, MEDTEQ+, Real Ventures, Anges Quebec, and AQC Capital, with the most recent disclosed funding activity in 2019.
Densitas firmographics
Firmographics- Name
- Densitas
- Legal name
- Densitas Inc.
- Website
- https://densitashealth.ca
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Densitas is a Halifax-based healthcare AI company providing the intelliMammo platform, which delivers automated mammography image quality, breast density, positioning quality, and breast cancer risk assessments deployed at mammography facilities, health systems, provincial screening programs, and academic centers across North America, the UK, and Germany.
- Ownership category
- akta.pro rank
Densitas industry classification
Industry- Product category
- Medical Imaging AI / Mammography Analytics Software
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Mammography & Breast Imaging Systems (HLAHABAF), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where Densitas is headquartered
LocationHeadquarters
- HQ city
- Halifax
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Densitas business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- SaaS/Software Subscriptions: Cloud-based AI platform delivered as subscription to mammography facilities, health systems, and breast imaging centers. Pricing likely per-facility or per-scan based on enterprise agreements.
Go-to-market motion3 records
Distribution channels7 records
Marketing channels7 records
Densitas product offering
Product offeringCore offering
Densitas builds and sells the intelliMammo AI platform — a cloud-based, vendor-neutral mammography analytics suite that runs automated breast density, image quality, positioning quality, and breast cancer risk assessments on standard DICOM mammograms for every exam. The platform is sold via subscription to hospitals, breast imaging centers, health systems, teleradiology providers, and provincial/national screening programs, with seamless PACS/RIS integration and supporting modules for analytics, compliance, equipment QC, CE tracking, and a GPT-powered assistant.
Product overview
Densitas offers the Densitas Breast Imaging AI Suite — a unified, end-to-end platform-plus-modules architecture comprising the intelliMammo core platform, densityAI deep learning breast density algorithm, qualityAI image quality evaluation, intelliRisk breast cancer risk management, and intelliMaven GPT AI assistant. Supporting modules include positioning/proficiency, advanced analytics, CE Tracking, Equipment QC, and compliance workflows. The suite covers the full breast care continuum from image acquisition to program management, providing on-demand clinical intelligence for mammography quality, breast density, and breast cancer risk for every mammogram.
Differentiator
Problem solved
Functional benefit
Brands
- intelliMammo®: AI-powered mammography quality analytics platform for breast cancer screening, providing image quality assessment, breast density evaluation, and positioning optimization.
- densityAI™
- qualityAI™
- intelliRisk™
- intelliMaven™
- intelliPGMI™
Products and services
- intelliMammo Core AI-powered platform for mammography quality that automatically generates breast density, clinical image quality, and breast cancer risk assessments for every mammogram. Provides real-time analytics for technologists at point-of-care and retrospective analytics for radiologists, QC technologists, and administrators at clinic and health system levels.
- densityAI Automated and standardized breast density assessment software using two distinct deep learning models that decouple quantitative percent mammographic density (0%-100%) from qualitative ACR BI-RADS 5th edition category (A, B, C, D). Processes 'for presentation' DICOM mammograms with seamless PACS integration.
- qualityAI Mammography image quality evaluation software generating standardized, reproducible assessments aligned with Canadian Association of Radiologists Mammography Accreditation Program (CAR MAP) image quality criteria and FDA MQSA EQUIP requirements. Provides enterprise-wide evaluation with automated flagging of poor quality.
- intelliRisk High-risk breast cancer patient management platform that supports NAPBC accreditation. Integrates breast density with clinical factors to provide standardized, reproducible patient-specific breast cancer risk estimates for individualized screening strategies and supplemental imaging recommendations.
- intelliMaven GPT AI add-on to the intelliMammo platform that answers complex mammography questions in clear, easy-to-understand narrative language. Provides real-time expert feedback on positioning techniques to technologists and operational insights for radiologists and managers.
Quantifiable outcome
- Mammograms meeting positioning criteria improved from ~51% to 86% baseline with structured QI programs
- +2 more outcomes
Companies that use Densitas
Customer profileNamed customers11 records
Segments5 records
Ideal customer profiles3 records
Densitas technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability10 records
Feature7 records
Densitas partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- TungstenQI PartnerscoreStrategic partnership combining Densitas' intelliMammo AI platform with TungstenQI's quality improvement methodology. Integrates AI-driven analytics with expert-guided interventions for sustainable mammography positioning improvement. Aims to help facilities refine positioning techniques, boost diagnostic accuracy, reduce unnecessary recalls, and improve patient outcomes through continuous QI programs.
- ACR Learning NetworkcoreCollaboration with ACR Learning Network in the Mammography Positioning Improvement Collaborative to advance quality standards. Part of broader initiative to standardize mammography positioning across U.S. facilities using AI-driven analytics.
- Medical Technology Management Institute (MTMI)coreStrategic collaboration integrating MTMI's educational content including embedded positioning videos into intelliMammo solution. MTMI provides expert instruction across imaging modalities with highly rated mammography courses and cross-training boot camps. Joint telehealth solution for customized technologist training curriculum.
- Atlantic Canada Health NetworkscoreProvince-wide deployment across Atlantic Canada including Horizon Health Network, Vitalité Health Network (New Brunswick), Health PEI (Prince Edward Island), Nova Scotia Health, and IWK Health. Groundbreaking intelliMammo AI platform deployment for screening mammography across multiple provinces.
- Mammography EducatorscoreFirst AI-powered telehealth technologist training platform. Co-founded by Louise Miller, world-renowned mammographer. Develops high-quality methods for breast imaging through education services and products. Provides live technologist training remotely informed by Densitas-generated technologist AI report cards.
- RAD-AID InternationalcorePartnership to establish AI-based decision support program for breast health in medically underserved regions. Provides low-resource institutions with education, clinical support, and hands-on training for sustainable mammography practices. Addresses global breast health disparities through responsible AI deployment.
- Nuance CommunicationscoreAI Marketplace accelerates AI development and adoption in medical imaging by connecting algorithm developers with subscribers' PACS, reporting, and worklist solutions across 6,500+ healthcare facilities and 70% of U.S. radiologists. Densitas densityai available through Nuance PowerScribe One and PowerScribe 360 Reporting. Also connected to Nuance Precision Imaging Network (PIN).
- DIMASOS 2 Trial (Germany)coredensitas densityai deployed in up to 24 clinics throughout Germany for major breast cancer screening trial. Led by Prof. Dr. Sylvia H. Heywang-Köbrunner. Trial tests combined mammography/ultrasound exams for early cancer detection. Densitas software provides breast density measurements to identify women for supplemental screening.
- TeleMammography SpecialistscoreInternational teleradiology services provider specialized in breast imaging. First U.S. beta user for densitas qualityai solution. Implementing densitas densityai for standardized breast density assessment. Over 60,000 women benefit annually through this partnership. Supports EQUIP guidelines compliance and real-time radiologist-to-technologist feedback.
- InteleradminorLeading provider of medical imaging software and services. Headquartered in Raleigh, NC and Montreal, Quebec with over 900 employees in offices across six countries. Nearly 2,500 healthcare organizations rely on Intelerad products. Densitas integration enables enterprise imaging customers to access AI-powered mammography quality solutions.
- iCAD, Inc.minorGlobal leader in AI-powered mammography analysis for breast cancer detection, density assessment, and risk evaluation. ProFound Breast Health Suite available in over 50 countries serving thousands of providers and millions of patients. Channel partnership for complementary market access.
- ScreenPoint MedicalminorTranspara AI for breast cancer risk assessment and screening workflow. Developed by machine learning and image analysis experts with input from world-renowned breast imagers. Partnership for integrated market offerings.
- BlackfordcoreAI platform providing actionable imaging information to reduce cost of care while improving diagnostic confidence and patient outcomes. Relevancy engine determines which studies to send each clinical application. Densitas integrated into Blackford Platform and Curated Marketplace for AI interoperability.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Densitas competitors and assessment
Company assessmentDirect peers
- Volpara Health: Volpara provides AI-driven breast density, image quality, and risk assessment software used by mammography clinics and health systems—competing with Densitas across the same densityAI / qualityAI use cases and a comparable SaaS go-to-market.
- ScreenPoint Medical: ScreenPoint's Transpara AI provides breast cancer detection, risk assessment, and screening workflow support—the most directly overlapping clinical use case with Densitas. Densitas lists ScreenPoint as a channel partner, confirming product-level comparability for breast imaging AI buyers.
- iCAD (ProFound Breast Health Suite): iCAD is a direct competitor offering AI for breast density, cancer detection, and risk assessment via the ProFound suite. Both companies target mammography facilities and breast imaging centers and even operate as channel partners—making iCAD the closest head-to-head comparison for Densitas.
Emerging players
- Lunit: Lunit's INSIGHT MMG is an FDA-cleared breast cancer detection AI used in mammography workflows. While Lunit is broader across multiple imaging modalities, its mammography product is a direct competitor for breast imaging AI budget and radiology workflow integration.
- Therapixel: Therapixel's MammoScreen is an FDA-cleared AI for mammography reading workflow, similar to densityAI and risk assessment modules. Therapixel is a focused European competitor pursuing U.S. market entry, comparable to Densitas in size and specialization.
Broad incumbents
- Hologic: Hologic is the dominant mammography hardware vendor (3Dimensions, Genius AI) and offers adjacent AI capabilities. While not a direct Densitas competitor on density/positioning software, Hologic's installed base and bundled AI offerings shape Densitas' competitive environment at the system level.
- GE HealthCare: GE HealthCare sells mammography systems (Senographe Pristina) and the iCAD-licensed MIA algorithm, and operates broader imaging IT platforms (Edison). As a broad incumbent, it competes with Densitas both at the modality-AI layer and at the imaging IT/integration layer.
Peers
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Densitas social profiles
Digital presenceDensitas compliance and trust
Trust signalCompliance2 records
Densitas financial estimates
Financial estimateRevenue estimate
Valuation estimate
Densitas leadership team
Management profileNumber of profiles
Profiles1 record
Densitas funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Densitas M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Densitas
What does Densitas do?
Densitas builds and sells the intelliMammo AI platform — a cloud-based, vendor-neutral mammography analytics suite that runs automated breast density, image quality, positioning quality, and breast cancer risk assessments on standard DICOM mammograms for every exam. The platform is sold via subscription to hospitals, breast imaging centers, health systems, teleradiology providers, and provincial/national screening programs, with seamless PACS/RIS integration and supporting modules for analytics, compliance, equipment QC, CE tracking, and a GPT-powered assistant.
Is Densitas a public or private company?
Densitas is a private company. It is classified as venture growth investor backed and is currently operating.
When was Densitas founded?
Densitas was founded in 2015. It employs 11 to 50 people.
Where is Densitas based?
Densitas is headquartered in Halifax, Canada, in the North America region.
How does Densitas make money?
One revenue line is on record: saaS/Software Subscriptions.
Who are Densitas's main competitors?
Direct peers on record are Volpara Health, ScreenPoint Medical and iCAD (ProFound Breast Health Suite). Emerging players are Lunit and Therapixel. Broad incumbents are Hologic and GE HealthCare. DeepHealth (RadNet subsidiary) is listed as a peer.
Does Densitas have an API?
No public API is recorded for Densitas.
What industry is Densitas in?
Densitas's product category is Medical Imaging AI / Mammography Analytics Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHABAF, Mammography & Breast Imaging Systems.